Scarica l'app Stockscreener
34.74
2.74%
-0.98
Dopo l'orario di chiusura:
34.74
Hemab Therapeutics Holdings Inc Borsa (COAG) Ultime notizie
Form 4 Hemab Therapeutics Holdings For: 25 September By Investing.com - Investing.com Canada
Director Walbert Keli's option carries a $35.72 exercise price at Hemab Therapeutics (COAG). - Stock Titan
Walbert Keli is listed as a director of Hemab Therapeutics (COAG) in an initial ownership statement. - Stock Titan
Hemab Therapeutics Holdings, Inc. (COAG) Stock Price, News, Quote & History - Yahoo! Finance Canada
Keli Walbert elected to Hemab board, joins Audit Committee - TradingView
Hemab Therapeutics Holdings, Inc. (COAG) stock price, news, quote and history - uk.finance.yahoo.com
Hemab Therapeutics Strengthens Board of Directors with Appointment of Keli Walbert - The Manila Times
Hemab Therapeutics (NASDAQ:COAG) Shares Down 5.7%What's Next? - MarketBeat
Hemab Therapeutics Holdings, Inc.(NasdaqGS:COAG) added to S&P Biotechnology Select Industry Index - marketscreener.com
Hemab Therapeutics Holdings, Inc.(NasdaqGS: COAG) added to S&P Global BMI Index - marketscreener.com
Hemab Therapeutics Holdings, Inc.(NasdaqGS:COAG) added to Russell 3000 Value Benchmark - marketscreener.com
Hemab Therapeutics Announces First Participant Dosed in Phase 1 Clinical Trial of HMB-003, an Investigational Therapy for the Management of Heavy Menstrual Bleeding - The Manila Times
Heavy menstrual bleeding affects 1 in 3 women. Hemab begins testing a new treatment. - Stock Titan
Hemab Therapeutics (COAG) FDA Approvals, PDUFA Dates & Drug Alerts 2026 - MarketBeat
Hemab Therapeutics (NASDAQ:COAG) Shares Up 7.6%Time to Buy? - MarketBeat
Opaleye Management Inc. Makes New Investment in Hemab Therapeutics Holdings, Inc. $COAG - MarketBeat
Hemab Therapeutics (NASDAQ:COAG) Trading Down 6.8%What's Next? - MarketBeat
Citadel Advisors LLC Takes Position in Hemab Therapeutics Holdings, Inc. $COAG - MarketBeat
Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Braidwell LP Purchases New Shares in Hemab Therapeutics Holdings, Inc. $COAG - MarketBeat
Biopharma IPO class of 2026: share price up 66% on average - BioWorld News
Hemab Therapeutics (NASDAQ:COAG) Trading Down 8.4%Here's What Happened - MarketBeat
AppLovin vs. CoreWeave: What Recent Revenue Trends Tell Investors - Yahoo Finance
Capital International Investors Establishes New Position in Hema - GuruFocus
symbol__ Stock Quote Price and Forecast - CNN
Novo Holdings A/S (COAG) discloses 9.0% beneficial stake in Hemab Therapeutics - Stock Titan
Avoro, Aghazadeh report 7.06% Hemab Therapeutics (COAG) ownership stake - Stock Titan
20 Years of Prix Galien USA Brings a New Nominee Class—Who Wins? - Stock Titan
HC Wainwright Cuts Earnings Estimates for Hemab Therapeutics - MarketBeat
Wedbush Maintains Hemab Therapeutics Holdings(COAG.US) With Buy Rating, Raises Target Price to $64 - Moomoo
Hemab Therapeutics (NASDAQ:COAG) Hits New 52-Week High After Analyst Upgrade - MarketBeat
Hemab Therapeutics (COAG): Capital International Investors discloses 7.7% ownership - Stock Titan
Hemab Therapeutics stock price target raised to $60 by H.C. Wainwright - Investing.com Canada
Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
COAG SWOT Analysis: Financial Challenges and Growth Potential Re - GuruFocus
FMR LLC Acquires Stake in Hemab Therapeutics Holdings Inc (COAG) - GuruFocus
H.C. Wainwright Maintains Hemab Therapeutics Holdings(COAG.US) With Buy Rating, Raises Target Price to $60 - Moomoo
Hemab Therapeutics Reports Q2 2026 Financials and Pipeline Progress in Latest 10-Q Filing - Kalkine Media
Hemab Therapeutics (COAG) widens loss but builds $457.5M cash war chest - Stock Titan
Hemab Therapeutics (NASDAQ:COAG) Price Target Raised to $60.00 at HC Wainwright - MarketBeat
Wedbush Adjusts Price Target on Hemab Therapeutics to $64 From $55, Keeps Outperform Rating - marketscreener.com
Form 8K Hemab Therapeutics Holdings For: 11 August By Investing.com - Investing.com South Africa
Hemab Therapeutics Gains FDA Backing to Advance Sutacimig Into Phase 3 Trial for Glanzmann Thrombasthenia - Minichart
Hemab Therapeutics' Q2 Net Loss Narrows - marketscreener.com
Earnings Flash (COAG) Hemab Therapeutics Posts Q2 Net Loss $0.80 a Share, vs. FactSet Est of $0.56 Loss - marketscreener.com
Hemab Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update - The Manila Times
Hemab Therapeutics reports Q2 2026 net loss of $24.2M, cash runway into 2029 after $317M IPO proceeds - TradingView
Hemab Unveils Peptide-Based Approach to Heavy Menstrual Bleeding - Stock Titan
Hemab Therapeutics (NASDAQ: COAG) investors detail 5.1% passive ownership stake - Stock Titan
Hemab Therapeutics (NASDAQ:COAG) Hits New 1-Year HighTime to Buy? - MarketBeat
FMR LLC reports 7.9% Hemab Therapeutics (COAG) stake on Schedule 13G - Stock Titan
Sofinnova group (NASDAQ: COAG) discloses 5.4% Hemab Therapeutics ownership on Schedule 13G - Stock Titan
SUTNTIB AB Tewox publishes its NAV for July 2026 - Yahoo Finance
Hemab Therapeutics (NASDAQ:COAG) Trading Down 4.8%What's Next? - MarketBeat
CCC Intelligent Solutions Holdings Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Hemab Therapeutics Holdings Ord Shs (Proposed) - TradingKey
Hemab Therapeutics Holdings, Inc. Revenue Breakdown – NASDAQ:COAG - TradingView
Ra Capital Nexus Fund Iv, L.p. Net Worth (2026) - GuruFocus
Biotech stocks lead healthcare's overbought list as earnings picks up (XLV:NYSEARCA) - Seeking Alpha
Mads Nikolaj Behrndt Eriksen Net Worth (2026) - GuruFocus
Biotech IPO gains crush numerous AI listings - PressReader
Biotech IPO gains crush AI listings with standout 55% return - The Edge Singapore
Biotech IPOs Surge 55% as AI Listings Lose Momentum - TradingView
Ananthram Sreenivasa Murthy Net Worth (2026) - GuruFocus
3.06%
2.55%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):